Related Experiment Video
Updated: Mar 15, 2026
Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
Published on: February 18, 2015
Stomatitis Powder Ameliorates Oral Ulcer Symptoms by Increasing Col11a1 Expression
Mianjie Wang1, Yulin Wang2, Wukai Ma3
1Department of Stomatology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, 550001, China.
Introduction:
Stomatitis Powder, a classic Traditional Chinese Medicine formula with heat-clearing and blood-cooling properties, is clinically used for treating Oral Ulcers (OU). However, its therapeutic mechanisms remain unclear. This study investigated the pharmacological mechanisms of Stomatitis Powder using RNA sequencing technology.
Methods:
We performed RNA sequencing of oral mucosal tissues before and after Stomatitis Powder treatment to identify Differentially Expressed Genes (DEGs). Pain-related genes (n = 820) were obtained from the HP_PAIN gene set in the GSEA database and intersected with the DEGs to identify pain-related DEGs. Protein-Protein Interaction (PPI) network analysis was then employed to screen for key genes. Finally, the bioinformatics findings were validated in an OU rat model.
Results:
Following data quality control, we identified 443 DEGs, which were intersected with pain-related genes to yield 20 candidate genes. Subsequent PPI network analysis identified four key genes (Col11a1, Col5a1, Enpp1, and Pth1r). In the OU rat model, Stomatitis Powder treatment was found to upregulate Col11a1 expression, alleviate mucosal tissue fibrosis, and accelerate ulcer wound healing, thereby improving OU symptoms.
Conclusion:
The results of the present study provide a scientific basis for the application of stomatitis powder to the treatment of oral ulcers using modern pharmacological techniques.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...